A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad in Subjects With Highly Active Relapsing Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 31 Jul 2018 Planned End Date changed from 1 Jan 2022 to 31 Dec 2021.
- 06 Jul 2018 Status changed from not yet recruiting to recruiting.
- 06 Apr 2018 Planned End Date changed from 30 May 2021 to 1 Jan 2022.